Artivion Inc (AORT)

Currency in USD
32.06
+1.14(+3.69%)
Closed·
After Hours
32.060.00(0.00%)
·
AORT Scorecard
Full Analysis
Net income is expected to grow this year
AORT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
31.0432.07
52 wk Range
21.9732.94
Key Statistics
Prev. Close
30.92
Open
31.04
Day's Range
31.04-32.07
52 wk Range
21.97-32.94
Volume
270.23K
Average Volume (3m)
393.95K
1-Year Change
22.74%
Book Value / Share
7
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AORT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
32.71
Upside
+2.04%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings downwards for the upcoming period

Artivion Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Artivion Inc Company Profile

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac and preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts, including E-vita Open NEO, E-vita Open Plus, ascyrus medical dissection stent hybrid prosthesis, E-vita THORACIC 3G products, and NEXUS products. It also offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries and aneurysmal iliac side branches; Tuva BX, a balloon-expandable peripheral stent graft to treat arterial ruptures, aneurysms, and other peripheral vascular system pathologies; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves, and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures for mitral chordal replacement; and pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Artivion Inc Earnings Call Summary for Q1/2025

  • Q1 revenue of $99M missed forecast, but EPS of $0.06 beat expectations; stock rose 4.75% in aftermarket trading
  • Full-year revenue guidance raised to 11-14% growth, with expected revenues between $423M and $435M
  • Strong growth in Latin America and EMEA offset North American decline; company maintains robust liquidity with 4.34 current ratio
  • U.S. launch of AMDS device and international expansion expected to drive accelerated growth in second half of year
  • Cybersecurity incident costs of $4.7M in Q1; company anticipates being free cash flow positive for the year
Last Updated: 05/05/2025, 22:34
Read Full Transcript

Compare AORT to Peers and Sector

Metrics to compare
AORT
Peers
Sector
Relationship
P/E Ratio
−70.6x−7.5x−0.5x
PEG Ratio
0.54−0.320.00
Price/Book
5.1x2.3x2.6x
Price / LTM Sales
3.9x3.1x3.3x
Upside (Analyst Target)
3.5%66.3%43.5%
Fair Value Upside
Unlock7.0%6.3%Unlock

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 32.71
(+2.04% Upside)

Earnings

Latest Release
May 06, 2025
EPS / Forecast
-0.01 / 0.0003
Revenue / Forecast
98.98M / 104.65M
EPS Revisions
Last 90 days

AORT Income Statement

People Also Watch

14.06
PONY
+7.82%
43.380
SMR
-2.36%
28.72
TGTX
-17.99%
49.30
TOST
+5.66%
76.41
OKLO
+6.88%

FAQ

What Stock Exchange Does Artivion Trade On?

Artivion is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Artivion?

The stock symbol for Artivion is "AORT."

What Is the Artivion Market Cap?

As of today, Artivion market cap is 1.50B.

What Is Artivion's Earnings Per Share (TTM)?

The Artivion EPS (TTM) is -0.51.

When Is the Next Artivion Earnings Date?

Artivion will release its next earnings report on 29 Oct 2025.

From a Technical Analysis Perspective, Is AORT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Artivion Stock Split?

Artivion has split 2 times.

How Many Employees Does Artivion Have?

Artivion has 1600 employees.

What is the current trading status of Artivion (AORT)?

As of 05 Aug 2025, Artivion (AORT) is trading at a price of 32.06, with a previous close of 30.92. The stock has fluctuated within a day range of 31.04 to 32.07, while its 52-week range spans from 21.97 to 32.94.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.